Search Results
New Study Shows 9/11 Responders Have Higher Rates of Leukemia
All 9/11 responders put their own lives at risk to save others from the events that occurred at the World Trade Center (WTC) on September 11, 2001, in New York City. Since then, several studies have shown elevated rates of cancers such as multiple myeloma, prostate cancer and thyroid cancer among first responders and those who worked nearby.
Impact of Insurance Type and Cost Sharing on Equity in Access to Oral Anticancer Medications for Blood Cancers
This project will evaluate the association of insurance type with insurer rejection and patient abandonment of new OAM prescriptions for blood cancers, overall and by sociodemographic factors. It will also evaluate the association of cost sharing with patient abandonment of OAM prescriptions for blood cancers and conduct simulations under alternative cost sharing scenarios to inform policy reform proposals among commercially insured enrollees.Surviving ALL: An Intimate Look at How Cancer Affected the Careers, Relationships & Fertility of Four Young Adults
A cancer diagnosis is a devastating blow for people of all ages, but presents special challenges for young adults. This period of life is usually a time of transition as they are embarking on journeys such as school, relationships and careers. A cancer diagnosis can bring their lives to a screeching halt in the midst of these new adventures.
Why Monthly Giving Matters
Giving regularly over time = giving patients and survivors the chance for more time.
Monthly giving really deserves more credit—credit as a predictable, impactful funding force for our lifesaving and life-changing work. For The Leukemia & Lymphoma Society (LLS), the reliability of a regular gift helps to sustain cutting-edge research and to provide the free resources and support blood cancer patients and survivors need to live longer, better lives.
It’s about ongoing generosity. It’s about creating a lasting impact.
And...
Etoposide
Etoposide is used to treat people who have certain types of blood cancer including Hodgkin and non-Hodgkin lymphoma. It is FDA approved for some types of lung and testicular cancer. This medicine often causes a temporary loss of hair. After treatment with etoposide has ended, normal hair growth should return.
Champions in myeloma research: A conversation with Urvi A. Shah, M.D. M.S.
March is Myeloma Awareness Month, and it’s also Women’s History Month. So what better time to spotlight LLS-funded women scientists who are driving discovery for myeloma patients.
In this first of my two-part series on myeloma researchers, I sat down with Urvi A. Shah, MD, MS, an Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center.
Every Year Counts: Celebrating My Healing from Hodgkin Lymphoma
Many blood cancer survivors remember the day they were diagnosed, and they never forget it. For Racheli Alkobey Peltier—Director of Diversity, Equity, and Inclusion at The Leukemia & Lymphoma Society (LLS)— when that date comes around, it’s a chance to mark her progress.
Each year, Racheli marks important milestones in her experience with blood cancer—taking time to reflect, feel gratitude, and look ahead. These dates are her “cancerversaries.”
Lymphoma diagnosis, survival rate by age, prognosis, and treatment
Table of contents:
3 Insights from a Clinical Trial Patient
The road to finding new and better cancer treatments often includes an important step: clinical trials. For patients with hard-to-treat diseases, these studies can be superhighways to the right treatment. A clinical trial can tell oncologists whether a new treatment works, how certain cancer types affect the body, and more.
Ibrutinib
Ibrutinib has been FDA-approved to treat:
- Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (SLL) with 17p deletion.
- Patients with Waldenström macroglobulinemia (WM).
- Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
5 Reasons why I’m grateful for LLS Volunteers
It’s National Volunteer Week, and I want to thank all our LLS volunteers for the time, energy, and commitment you give to our organization in service of blood cancer patients and their families. Through your many acts of kindness, compassion, and generosity, you are helping patients live longer, better lives. All of us at LLS are so grateful for you—all year long.
Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.
3 Things You Might Like to Know About Being Newly Diagnosed
A cancer diagnosis is a pivotal moment in a person’s lifetime.
From that point forward, it’s a part of who you are. It shapes how you think about the world—through the lens of your diagnosis and what’s important to you.
FDA Approves First CAR T-Immunotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) recently announced approval of brexucabtagene autoleucel (Tecartus®) as the first and only CAR T-cell treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Roughly half of all ALL cases occur in adults, and unlike pediatric ALL, adults have historically had a poor prognosis. This approval, which follows an FDA Breakthrough Therapy Designation and priority review, is a meaningful advance for these patients.